U.S., April 8 -- ClinicalTrials.gov registry received information related to the study (NCT07514338) titled 'Open Label Extension to Assess Long Term Safety and Efficacy of KL1333 in Patients With Primary Mitochondrial Disease' on Feb. 24.
Brief Summary: The purpose of this study is to investigate if the study medicine, KL1333, is safe, well-tolerated and effective long-term in improving the symptoms of fatigue and impacts on daily living and functional capacity (physical abilities) in people with PMD.
Study Start Date: June 09
Study Type: INTERVENTIONAL
Condition:
Mitochondrial Diseases
Intervention:
DRUG: Napazimone
Product: KL1333 (international nonproprietary name: napazimone) Dose: Each subject will be up-titrated to his/her ma...